Rilpivirine (RPV)

DRUG2 trials

Sponsors

Janssen Infectious Diseases BVBA, ViiV Healthcare

Conditions

HIV InfectionsHuman Immunodeficiency Virus Type 1

Phase 1

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

CompletedNCT02547870

Janssen Infectious Diseases BVBAHuman Immunodeficiency Virus Type 1

Start: 2015-08-14End: 2016-04-26Updated: 2018-11-14

Unknown Phase

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

CompletedNCT04019873

ViiV HealthcareHIV Infections

Start: 2019-11-18End: 2023-12-05Updated: 2025-01-22